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ABSTRACT 
 
Therapeutic proteins represent an essential piece of a health management plan for 
diseases such as diabetes, cancer, hemophilia, Crohn’s Disease, and myocardial 
infarction. These proteins, however, must be maintained in their correct, biologically 
active conformation throughout processing, transportation, and delivery. This 
requirement poses serious engineering challenges because of a protein’s susceptibility to 
thermodynamic instabilities resulting from the weak bonds driving the tertiary structure 
of the molecule.  A particularly problematic type of protein degradation is aggregation. 
Administration of aggregated proteins, a particularly problematic degradation form, can 
have dire consequences, including blocking a patient’s responsiveness to therapy, 
inducing immunogenicity, and even anaphylactic shock and death. Normal shipping and 
delivery methodologies are suspected of causing protein aggregation after the normal 
quality control process has been completed. This work investigates the effect of acoustic 
cavitation on protein aggregation as a function of impurity level, gas-liquid surface to 
value ratios, protein concentration, solution viscosity, density, surface tension, and 
nebulization time. A 0.2M and pH of 4.2 Glycine buffer solution was utilized with IVIg 
protein at 0.5, 1.0, 5.0, and 10.0 mg/ml and 20ºC. Protein aggregates were characterized 
using Microflow imaging and NanoSight tracking analysis. Transient cavitation and 
formation of radicals was monitored using classical iodine assays.  Higher protein 
aggregation is observed in solutions that initially contain greater amounts of impurities or 
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have a larger contact area with the gas interface. Aggregate production in hyper clean 
solutions, with no gas-liquid interface, initially increases with protein concentration, but 
eventually decreases at high concentrations.  
      In contrast, aggregation rates in hyper clean solution with a gas-liquid interface 
continue to fall with increasing protein concentration.  The size of the particulate in these 
two conditions suggests different degradation pathways. The small sizes when a gas 
interface is available are likely a result of the large area over which the process takes 
place. The effect of concentration is actually an effect of diffusion or availability for 
proteins at the surface. The large sizes found in conditions with no gas interface suggest a 
much more concentrated process consistent with an intense energy release at a single 
location. Moreover, monitoring of the formation of I3- from iodine as a function of 
nebulization time shows increasing production or radicals. All this supports the 
hypothesis that ultrasonic pressure waves in protein solutions cause transient cavitation 
which upon bubble implosion release hydroxyl radicals that can attack the protein in 
solution.  In this circumstance, a rise in viscosity at higher protein concentration inhibits 
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CHAPTER ONE: MOTIVATION 
Introduction 
 
Protein therapeutics are a valuable clinical tool in the fight against diseases and 
conditions such as cancer, diabetes, hemophilia, Crohn’s Disease, and myocardial 
infraction [1].  The number of commercially available protein-based products in the US 
has gone from three in the late 1980s to nearly 150 today [2].  Physical degradation of 
proteins has become a subject of considerable interest within the pharmaceutical industry 
as the number of therapeutic protein products has increased in recent years.  This interest 
is driven by the fact that in order for protein therapeutics to be effective, they must 
remain in their correct, biological active state throughout production, transportation, and 
delivery to patients.   The ability for a therapeutic protein to demonstrate human health 
benefits, as well as become an economically viable, FDA approved drug, hinges on 
relatively weak molecular stability and high susceptibility to degradation [2].   
Protein Degradation 
 
Processes that modify covalent bonds within a protein, such as deamidation, 
oxidation, and disulfide bond shuffling, are known as chemical degradation.  In this type 
of protein degradation, new chemical entities are generated through the making and 
breaking of covalent bonds.  Conversely, physical degradation involves protein 
instabilities that lead to changes in physical state without change in chemical composition 
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[2].  These instabilities can lead to undesirable phenomena including protein unfolding, 
adsorption to surfaces, and aggregation.  For the purpose of this research, all references to 
protein degradation will be in the context of physical degradation. 
Protein Aggregation 
 
For protein therapeutics to work, proteins involved must be folded into three 
dimensional globular structures known as the native state [3].  The loss of native protein 
structure, resulting in a fully or partially unfolded state, can lead to the formation of 
aggregates held together by hydrophobic attraction.  This phenomenon occurs when 
specific subunits of one molecule are ‘attracted’ to specific subunits of another, 
interacting in an intermolecular manner [5].  Continued propagation leads to the 
formation of large aggregates.  Conformational stability of a protein’s native state relies 
on many factors such as amino acid sequence, pH, temperature, and concentration [5].  In 
high concentrations, there is a thermodynamic competition between a protein’s properly 
folded native state and aggregation due to partially folded intermediates [1-3,5].   
Protein aggregation within pharmaceuticals is a subject of heightened interest for 
the bio-pharma industry because of possible adverse effects upon administration to 
patients [1-5].  Studies have shown that aggregated therapeutics can cause blocking of 
responsiveness to therapy and onset of immunogenicity [4-7].  Aggregation often 
happens in bioprocessing during cell culture, purification, formulation, and fill finish 
operations [7]. Because of this, the FDA has guidelines for the size of particles allowable 
for finished drug products.  However, since the aggregated state has a lower free energy 
than the native state, it has been shown that environmental factors during storage, 
shipping and delivery can cause aggregation.  It has also been suggested that aggregates 
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smaller than the FDA’s requirements could be responsible for immunogenic reactions [9].  
For these reasons, it is necessary for pharmaceutical researchers to understand the cause 
and mechanism of therapeutic protein aggregation.   
Cavitation 
 
Cavitation is the formation and collapse of cavities in incompressible liquids [29].  
In 1917, Lord Rayleigh predicted enormous local temperatures and pressures at the 
location of the collapse.  This collapse of bubbles, caused by cavitation, produces intense 
local heating and high pressures with very short lifetimes [29].  Cavitation can take place 
anywhere the local pressure in a liquid drops below the vapor pressure and a cavity or 
bubble is formed.  Well known examples of this are propellers rotating through a liquid 
where bubbles can be seen forming behind the trailing edge of the prop blade.  This 
process can occur in many bioprocessing steps such as pumping, mixing, and post filling 
processes; post filling processes can include over agitation of a vial or ultrasonic 
nebulization for pulmonary drug delivery.  Although it is recognized that no single 
mechanism for the aggregation of proteins exists, it is well understood that all of the 
possible mechanisms must involve thermodynamic energy needed to drive proteins from 
their native state [2,5].  Many potentially damaging conditions including air-water 
interface, turbulent vortexing, freeze-thaw, extreme temperature, and chemical 
degradation have been heavily studied by pharmaceutical researchers [8].  However, 
despite parallels between the thermodynamic effect of bubble collapse and the known 
causes of protein aggregation, very little has been written about cavitation as a 





Acoustic cavitation is the formation, growth, and implosive collapse of bubbles in 
liquids irradiated with high-intensity ultrasound [29].  Two types of acoustic cavitation 
exist: stable and transient.  Stable cavities grow or shrink and then oscillate about some 
equilibrium size, often existing for many acoustic cycles.  Transient cavities exist for 
only a few cycles until the forcing frequency is near its resonance; Figure (1).  These 
bubbles can expand to several orders of magnitude larger than their original size before 
imploding.  For the duration of this paper, any statements involving cavitation will be in 
reference to acoustic cavitation.   
Figure 1.  Visual schematic of stable and transient cavitation.  Above: Bubble forms and 
oscillates through many acoustic cycles during stable cavitation.  Below: Bubble forms 
and grows until implosion during transient cavitation.   
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Suslick, et al. (1999) was able to show that the collapse of bubbles in a multi-
bubble cavitation field produces hot spots with effective temperatures of ca. 5000 K, 
pressures of ca. 1000 atm, and heating and cooling rates above 10^10 Ks-1.  Experiments 
where it would be possible to isolate and study these extreme conditions in the presence 
of proteins could lead to a better understanding of cavitation as a mechanism for protein 
aggregation.  We hypothesize that protein therapeutic exposure to cavitation alone will 
not only result in the formation of aggregates, but by varying parameters such as 
nebulization time, sample volume, solution properties, and concentration, methods of 
mitigation for protein degradation by cavitation will be identified.   
Ultrasonic Nebulization 
 
An ultrasonic nebulizer is a device that uses piezoelectric effect to generate high-
frequency acoustic energy, which forms aerosol droplets by cavitation [22].  These 
devices are used for the pulmonary delivery of therapeutic proteins for diseases such as 
cystic fibrosis.   Most nebulizers on the market today are small, portable, and inexpensive 
machines, making them a perfect model system to study the effects of cavitation on 
protein therapeutics.  Pressure waves transmitted through a liquid volume alternatively 
expand and compress until tension forces on nucleation sites are sufficient to vaporize 
small volumes of liquid [29].  In water, the thermal degradation of water molecules leads 
to the formation of hydrogen atoms and hydroxyl radicals.  Studies have shown that DNA 
can serve as a nucleation site for bubble formation [20].  By that rationale, the existence 
of protein aggregates acting as nucleation sites within a fluid volume would only add to 
propagation of aggregates due to energy transfer from increased cavitation.  Thus if the 
liquid volume within an ultrasonic nebulizer could be isolated, its contents post 
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nebulization would be a representative sample of protein therapeutics exposed to 
cavitation in the absence of outside environmental factors.   
Aggregate Characterization 
 
Several well-known studies have been conducted showing adverse effects of 
protein aggregates in the micron as well as nanometer range.  In some cases, these 
aggregates are below the particle size limits for acceptable protein formulations imposed 
by the FDA [9].  Due to known issues of protein immunogenicity in aggregated protein 
formulations, it is important to characterize size, size distribution, and aggregate 
concentration.  This process is not trivial as protein aggregates are typically very 
heterogeneous, with sizes ranging from a few nanometers to several micrometers.  Small 
aggregates in the nm range have recently been implicated as the cause of 
immunogenicity; therefore, it is important to characterize particles at a very small scale 
[9].  Until recently, this task was almost impossible due to the limitations of particle 
counting instrumentation.  Particle characterization for this experiment utilized two 
relatively new technologies which take advantage of optical techniques and innovative 
software to get accurate particle size distributions. 
Micro-flow Imaging 
 
It has been common practice for years in pharmaceutical manufacturing to 
complete visible and sub-visible particulate testing of therapeutics to ensure their safety 
and suitability for clinical use [9].  Currently, the FDA has guidelines for acceptable 
numbers of particles >10 and >25 µm.  However, as previously explained, it may be 
important to measure the concentration of protein aggregates to at least one, maybe two 
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orders of magnitude smaller to avoid potential immunogenic response.  Also, since the 
shape of protein aggregates are variable and “fibril-like” in nature, it is important to use a 
counting device that does not rely on spherical and opaque particles for accurate counts 
[10, 12-15].   In order to achieve particle characterization from 2 µm and larger, Micro-
Flow Imaging (MFI™) is utilized.  By capturing digital images of particles suspended in 
a fluid as they pass through a sensing zone, MFI is able to automatically analyze a sample 
and provide a digital archive of parameters such as equivalent circular diameter (ECD), 
Feret diameter, aspect ratio, circularity, and intensity [13-17].  With the added benefits of 
instrument automation, high sensitivity, a broad size range, and requiring only a limited 
amount of sample for analysis, MFI offers advantages that cannot be matched by manual 
microscopy [13].   
MFI’s software exports particle size and concentration data in the form of an 
excel spread sheet that can be easily formatted into graphs for interpretation.  Figure (2) 
is a particle size vs. particle concentration graph that is representative of the data gathered 
during these experiments. 
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Figure 2.  Representive graph of data gathered in the µm range by MFI.  Particle 
concentration as a function of particle size for samples analyzed before nebulization pre-
neb (blue) and nebulized for 3 (red), 7 (green), 11(purple) and 15 (light blue) minutes 
respectively.   
 
Nanosight Tracking Analysis 
 
 Recent reviews in protein aggregation have outlined the importance of analyzing 
sub visible particles in the nanometer range [9].  Although standards have been set in the 
µm range, it has been shown that particles down to the 0.1 µm size could be responsible 
for immunogenic response in patients.  Following current standards and ignoring sub 
visible particles could result in adverse events in patients after commercialization, even in 
situations where the product was deemed safe and effective in clinical trials [9]. This 
research intends to analyze samples for particles in the submicron range with the use of 
Nanoparticle Tracking Analysis (NTA™), which is an innovative system for sizing 
particles from about 30-1000 nm.  Combining laser light scattering microscopy with a 
charge-coupled CCD camera, NTA enables the visualization and recording of 
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nanoparticles in solution.  This allows the NTA software to identify and track individual 
nanoparticles moving under Brownian motion [11,12].   
Nanosight’s software exports particle size and concentration data in the form of 
an excel spread sheet that can be easily formatted into graphs for interpretation.  Figure 
(3) is a particle size vs. particle concentration graph that is representative of the data 
gathered during these experiments.  
Figure 3.  Representive graph of data gathered in the nm range by NTA.  Particle 
Concentration as a function of particle size for samples analyzed before nebulization 
(pre-Neb), and after 15 minutes of nebulization with nebulizer set up for No-Space (red), 




In the following experiments, intravenous immunoglobulin (IVIg) will be used as 
a model proteinaceous compound.  For over 25 years, IVIg has been used in the treatment 
of autoimmune and inflammatory diseases.  It consists of IgG obtained from pools of 
plasma of several thousand healthy blood donors [24].  Previous studies have indicated 
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nebulization IVIg as a good means of drug delivery for infants [43].  However, IVIg 
works through many complex mechanisms that modulate the activation and neutralization 
of B and T lymphocytes and pathogenic autoantibodies.  Given this mechanism of action, 
it can be assumed that aggregated IVIg will interact with the immune system and that 
aggregation of IVIg has the potential for adverse immunogenic response.  Thus, IVIg is a 
well suited model proteinaceous compound for these experiments.   
Outline 
 
This thesis will characterize protein aggregation by means of ultrasonic 
nebulization to determine the impact of viscosity, density, surface tension, gas contact 
area, impurities, and exposure time on protein aggregation.  Our aim is to provide 
evidence that transient cavitation induces protein aggregation in therapeutics, and through 
investigation of fluid properties, suggest strategies for mitigation of aggregate formation.  
We hypothesize that ultrasonic nebulizers induce transient cavitation, and that proteins 
nucleate this cavitation much like plasmid DNA.  This will be done through classical 
iodine assays and altering variables such as concentration, sample volume and 
nebulization time.  Finally, solution properties such as viscosity, density and surface 










CHAPTER TWO: MATERIALS AND METHODS 
Intravenous immunoglobulin (IVIg) is a protein drug product prepared from pools 
of blood plasma from at least 3000, but up to 100,000 individuals.  It is comprised of a 
broad range of immune antibodies directed to pathogens and foreign antigens, and has 
been reported to have a beneficial effect on scores of immune mediated diseases [24].  
IVIg protein was obtained from a pharmacy in the form of the drug product Gamunex 
(Talecris Biotherapeutics, Durham, NC), stored in 1.0 ml aliquots at 100 mg/ml 
concentration and used as a model proteinaceous compound for aggregation.  Four 
protein concentrations were chosen (0.5, 1.0, 5.0 & 10.0 mg/ml) that represent dosages 
used in IVIg therapeutic administration.  Fluid property characterization was done with a 
model CVO (Bohlin Instruments, Inc, UK) viscometer to determine viscosity at each 
concentration.  Surface tension was determined using capillary action techniques.  
Formation of triiodide ions (I3
-
) formed by the oxidation of potassium iodide (KI) during 
nebulization was analyzed using a USB-ISS-UV/VIS (Ocean Optics, Inc., Dunedin, FL) 
UV-Spectrometer.   Dilutions of 10.0 mg/ml were purified with ultracentrifugation using 
an Optima™ LE-80K Ultracentrifuge (Beckman Coulter, USA).  Particle matter such as 
protein aggregates created during nebulization of IVIg protein were analyzed at the µm 
size using  Micro-flow Imaging™ (MFI) model DPA 4100 (Brightwell Technologies 
Inc., Ottawa, Canada).  Sub-micron particle characterization was performed using a 
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Deionized water (DI) from Milli-Q integral ultrapure water system (EMD 
Millipore, Billerica, MA); sodium hydroxide (NaOH), hydrochloric acid (HCl), glycine 
and potassium iodide (KI) (Sigma-Aldrich®, St. Louis, MO); 0.22 µm MILLEX®GP 
sterile syringe filters (Millipore, Co., Billerica, MA); Hellmanex (Hellma®, Plainview, 
NY); IVIg protein from drug product Gamunex (Talecris Biotherapeutics, Durham, NC). 
Sample Preparation 
 
First, buffer was made from glycine powder mixed with ultrapure DI water from a 
Milli-Q to a 2.0M buffer stock solution and titrated to pH 4.2 using HCL and NaOH.  
When needed, the 2.0M glycine buffer was diluted using DI water to 0.2M and re-titrated 
to pH 4.2 due to the acetic nature of DI water.  Sterile 0.22 µm syringe filters were used 
along with a 15 ml syringe to filter all buffers for storage, and before use.  Buffer was 
always stored in a refrigerator at 5°C when not in use.  1.0 ml aliquots of 100.0 mg/ml 
IVIg protein were obtained for use as the model proteinaceous compound for this 
experiment. Concentrated 100.0 mg/ml IVIg was pipetted into 9.0 ml of the 0.2M glycine 
buffer to make 10.0 ml of 10.0 mg/ml IVIg solution.  This pre-centrifuged solution was 
then loaded into an ultracentrifuge and spun down to remove all particles >100 nm, 
which is larger than native IVIg proteins.  After ultracentrifugation, the purified IVIg 
solution was diluted into the three other concentrations (0.5, 1.0 & 5.0 mg/ml) as needed 
for the experiments using filtered 0.2M glycine buffer.  Particle composition of glycine 
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buffer was tested before every dilution and experiment using MFI and NTA.  All samples 
were colorless, free of visible particles and possessed viscosity ranging from that of water 
to several times water depending on concentration. When not in use, all samples were 
stored in a refrigerator at 5°C.  No sample was stored for longer than 72 hours before use.  
All experiments were conducted at room temperature (18-25°C).  Samples removed from 
the refrigerator were left out at room temperature for ~10 min in order to normalize 
temperature and reduce any air bubbles in the solution.   
Ultracentrifugation 
 
In order to purify the samples before nebulization and avoid adverse effects of 
filters on the protein mixture, ultracentrifugation was used to dispose of particles >100 
nm in size within the solution.  It is important to ensure the solution is ultrapure because 
existing particles are known to act as nucleation sites for nonnative protein aggregation 
and therefore could create variability within samples [1]. To do this, a rough estimation 
was calculated using Stokes Law (Equation 1) in order to determine the settling velocity 
of small particles within the solution where    is sedimentation velocity,   is particle 
diameter,    is particle density,    is liquid density,   is viscosity of liquid, and   is 
gravitational acceleration.  
Stokes Law of Sedimentation 
   
  (      )
     
 
 This estimation is ‘rough’ in that assumptions must be made regarding the shape 
and density of the particles being assessed.  In order for Stokes Law to work, particles 
[ 1 ] 
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must be assumed to be spherical.  It is thus determined that the settling velocity for 100 
nm particles is ~4.92 cm/hr.  In order to facilitate all the particles settling at the bottom of 
a 30 ml test tube, the samples were spun at 112,000g for three hours, which corresponds 
to 25K RPM using a SW-28 rotor. After samples were placed inside the sample tubes and 
attached to the rotor, the centrifuge was vacuum sealed and kept at 5°C for the duration of 




A MABISMist™ II Ultrasonic Nebulizer Model 40-270-000 (MABIS Healthcare, 
Inc., Lake Forest, IL) was chosen as the device to induce cavitation during this 
experiment.  This nebulizer operates at a frequency of 2.5 MHz, 10 watts of power and 
uses the piezoelectric effect to generate high-frequency acoustic energy which generates 
aerosol droplets by cavitation [23].  The particles created by this nebulizer are in the 
range of 3-9 µm as measured by Phase Doppler Particle Analyzer [20], however for the 
majority of this experiment, impaction of the impinging jet is such that secondary droplet 
formation does not occur and the sample volume is never converted to aerosol.  All 
experiments, except those testing volume dependencies, were carried out according to 
manufactures specifications with a maximum sample volume of 8 ml.  All experiments, 
except those testing time dependencies, were run for a total of 15 min at the high setting.   
Sample cups used to hold the sample volume were rinsed thoroughly with 
ultrapure DI water followed by 15 minutes of nebulization on high with filtered glycine 
buffer to remove any further particles through sonication.  DI water was also used to rinse 
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the sample cup between successive runs.  To avoid particle accumulation between runs, 
the glass plug, rubber gasket and rim of the nebulizer were wiped down with 90% IPA 
and allowed to dry before further use.  The DI water reservoir was also changed out 
between runs due to a 15° C temperature increase after use.  A photographic diagram is 
displayed in Figure (4).   
 
Figure 4. Left: MABISMist™ II Ultrasonic Nebulizer Model 40-270-000.  Right: 




Samples of IVIg were diluted from 100 mg/ml to concentrations of 1.0, 5.0, 8.0 
and 10.0 mg/ml in order to get a representative distribution of viscosities between 0 
(Water) and 10.0 mg/ml.   All samples are run on a model CVO Bohlin Instruments 
Viscometer with a C14 ‘cup and bob’ coaxial cylinders.  The bob is made out of 
Titanium and the Cup stainless steel.  2.0 ml samples of each concentration were pipetted 
into the cup and run for each analysis.  The dynamic viscosity (ƞ) for each run is 
calculated using an Arrhenius function (Equation 2) built into the software of the 
Glass Plug 
Sample Volume 





viscometer where (c) is pre-exponential factor, (k) is the exponential constant, and (t) is 
the absolute temperature.   
Arrhenius Function 
     
 
  
All concentrations were run 12 times and an average viscosity was calculated using an 
average of all the runs.   
Density 
 
Samples of IVIg were diluted from 100 mg/ml to concentrations of 0.5, 1.0 5.0 
and 10.0 mg/ml.  A weigh boat was placed into the A&D model GR-202 (A&D®, 
Ablingdon, UK) analytical balance and the reading was zeroed. A volume of 5.0 
milliliters of each concentration was loaded into the weigh boat one at a time with a 
pipette.  The balance was allowed to stabilize and mass measurements were recorded for 
each concentration.  This process was repeated five times for ultrapure DI water and each 
concentration.  The density at each concentration was found by solving the density 
equation (Equation 3) where (ρ) is the density of the fluid in g/cm^3, (M) is the mass in 








[ 2 ] 





Samples of IVIg were diluted from 100 mg/ml to concentrations of 0.5, 1.0, 5.0 
and 10.0 mg/ml.  Each concentration, along with ultrapure DI water was pipetted into 
cuvettes and labeled by their respective IVIg concentration.  All cuvettes were filled 
completely so no meniscus was observed at the top edge.  The cuvette was brought to the 
glass capillary tube suspended from a fixed anchor in order to ensure that the angle with 
respect to gravity and position of the capillary tube within the in the liquid volume 
remained unchanged. The depth of placement was also maintained from test to test. 
Digital photographs were taken of the cuvette to accurately measure the contact angle and 
the resulting height (ΔH) of the liquid volume within the capillary.  This was done three 
times for each concentration and DI water.  Between runs the capillary and cuvette were 
thoroughly washed using DI water and dried using dry, filtered house air. The capillary 
was tapped to ensure no air bubbles stopped the wicking of the fluid into the tube. 
Measurements were made from the lowest to highest concentration to reduce the impact 
of residual impurities. 
The photographs were then uploaded onto a PC and normalized to actual size so 
ΔH could be determined by measuring with a ruler.  Using the known value of 7.28E-2 
N/m for the surface tension of DI water at 20° C, the inner diameter of the capillary tube 
was determined.  Rough estimations for the angle of the meniscus (Ɵ) were determined 
by magnifying the photograph of the meniscus inside the capillary tube and sketching a 
right triangle with Ɵ at the edge where the meniscus meets the sides of the glass capillary.  
By measuring the lengths of the opposite side and hypotenuse, the inverse sine of Ɵ was 
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taken for all concentrations.  Finally, surface tension (T) was calculated by solving the 
equation for capillary action (Equation 4) where ΔH is the height of the liquid volume 
within the capillary tube, ρ is the experimentally measured density, r is the radius of the 
capillary tube, g is the acceleration due to gravity, and Ɵ is the angle of the meniscus.   
Capillary Action 
    
        
   
 
Figure (5) shows an example of a representative photograph taken of a cuvette 
and capillary tube, as well as a zoomed in image of a meniscus within a capillary tube.  A 
right triangle is drawn in and labeled with the opposite side (0), hypotenuse (h) and angle 
of meniscus (Ɵ).   
                   
Figure 5.  A: A digital photograph, representitive of photographs taken in triplicate at 
each IVIg concentration.  B: A magnified in image of the of the meniscus and right 
triangle to calculate the angle of meniscus.   
A B 
 





A 100 mg/ml sample of IVIg was diluted to 1.0 and 10.0 mg/ml concentrations.  
Based on previous work using this well-established method to quantitatively monitor 
transient cavitation [19], it is known that triiodide ions are formed by the oxidation of KI.  
Initial experiments at traditional KI concentrations yielded no results, because IVIg is a 
good scavenger of    or the intermediates. Therefore to test for radical formation in the in 
the presence of IVIg protein, an elevated concentration was required. The optimal 
concentration was determined through a set of experiments accessing the signal to noise 
ratio.  
1.0 ml of the initial concentration of 200 mM KI was added to 9.0 ml of both 1.0 
mg/ml and 10.0 mg/ml protein solutions.  8.0 ml samples were then placed into the 
sample cup and nebulized on high for 15 min.  The nebulizer was stopped briefly at 3, 6, 
9, 12, and 15 minutes in order to remove a sample volume of 200 µl from the sample cup.  
This sample was then diluted to a total volume of 1.0 ml and placed in a plastic cuvette 
with a 0.4 cm path length and immediately analyzed using a USB-ISS-UV/VIS (Ocean 
Optics, Inc., Dunedin, FL) UV-Spectrometer.  The UV-Spectrometer was tested for 
operational integrity using known UV spectral identities for proteins and KI [31].  During 
triiodide analysis, purified glycine buffer and IVIg protein were used as the blank so only 
the iodine spectrum were visible.   
Under these conditions no triiodide ions were detected for either concentration of 
IVIg. Others have found that IVIg itself was a scavenger of free radicals (private 
conversations with the Randolph Lab), and therefore an abundance of KI might be 
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necessary in order to form detectable concentrations of triiodide. Several concentrations 
of KI were attempted with the best results near saturation. A solution of saturated KI 
(8.675 M) was made.  Again, 1.0 ml of this new KI solution was added to 9.0 ml of both 
1.0 and 10.0 mg/ml IVIg and immediately analyzed for triiodide ions.  Absorbance values 
were measured and recorded at 10 nm increments for 300 – 400 nm wavelengths.  
Absorbance values at the 350 nm peak were used to solve the Beer-Lambert relationship 
and calculate concentrations of triiodide ion.   
Concentration of I3
-
 was determined using the Beer-Lambert Law (Equation 5) 
where A is absorbance at 350 nm, e is molar absorptivity, b is the path length of the 
cuvette used, and c is the concentration of solution.  The known molar absorptivity of     
at 350 nm is 2.32E4 L/mol*cm [34].  Path length of the cuvettes used is 0.4 cm. 
Beer-Lambert Law of Absorbance 
      
Micro-Flow Imaging 
 
Measurements of particles 2 – 40 µm in size were performed using a Brightwell 
Technologies Inc. MFI model DPA4100 located at the University of Colorado, Anschutz 
Medical Campus.  Prior to each sample analysis, filtered glycine buffer was flushed 
through the flow cell, and analyzed to ensure a clean baseline before particle sample 
analysis.  All samples were allowed to sit at room temperature for at least 10 minutes 
after sample preparation to remove any air bubbles that could be picked up during 
analysis by the MFI.  Using a pipette, a 1.0 ml volume was loaded into the flow cell dock 
and drawn into the system at a rate of 0.22 ml/min.  During each run, 0.1 ml of fluid was 
[ 5 ] 
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allowed to purge through before particle analysis began and a total of 0.8 ml of fluid was 
analyzed.  For each sample, a total of three runs were conducted and averaged for further 
analysis.  A negative control was conducted using unprocessed, filtered glycine buffer.  
Counts from the controls are reported, but not subtracted from the final particle counts for 
all other samples.  Between sample analyses, the flow cell was cleaned by purging 1.0 ml 
of Hellmanex (Hellma®, Plainview, NY) and finally flushed with ultrapure DI water 
until cleanliness of the flow cell was ensured.   
Images of protein aggregates larger than 20 µm were captured during analysis and 
referenced against images from literature.  Although protein particles are highly 
heterogeneous in shape, common features of large ribbon-like aggregates can be 
distinguished as shown in Figure (6).   
 
                                                          
Figure 6.  MFI image from current data compared with one from previous publication 
[14]. 
 
 MFI data was collected and interpereted using Excel software.  Since we are 
interested in the total amount of particles within a size range, the integrated sum of 
particles per ml are reported for each variable respectively. Total particle concentrations 
per ml were determined by summing the values from 2 to 40 µm for each run.   
 
Image of Protein Aggregate from MFI data. 
Image of Protein Aggregate from 
Sharma, et al. 2010. 
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NanoSight Tracking Analysis  
 
Measurements of particles 1 – 1000 nm in size were performed using a 
NanoSight, model LM20 (NanoSight, Amesbury, United Kingdom).  Samples were 
introduced to the 0.3 ml sample chamber through a peripheral injection site using 
disposable lure-slip syringes (National Scientific, Rockwood, TN), until liquid reached 
the tip of the nozzle on the opposite side.  Excess sample remaining in the disposable 
syringe was injected into the sample chamber until a drop was purged from the nozzle on 
the opposite side between runs to enable the greatest amount of homogeneity among runs 
in each sample set.  In total, less than 1.0 ml was analyzed for each sample.  All 
measurements were performed at room temperature immediately after samples were 
nebulized.   
The software used for capturing recordings of the protein aggregates and 
analyzing the data was the NTA 2.0 Build 127.  Samples were recorded for 60 or 90 
seconds depending on particle concentration with lower concentrations being recorded 
for the later.  Figure (7) shows an example of the viewing frame recorded by NTA 
software.  Sub-micron particles can be seen as white dots with rings around them.  
Samples were run a total of 5 times and averaged before further analysis.   
NTA data were collected and interpereted using Excel software.  Since we are 
interested in the total amount of particles within a size range, the integrated sum of 
particles per ml are reported for each variable respectively. Total particle concentrations 











An 8 ml sample of 1.0 mg/ml IVIg was placed into the sample cup with the 
nebulizer set up so the glass plug sits just above the internal reservoir volume level.  As 
the sample was nebulized, the glass plug restricted the jet created by the ultrasonic field 
such that no vapor particles were created.  The internal volume was thus exposed to the 
smallest amount of gas/liquid interface and agitation within the sample appeared 
negligible.  Figure (8A). 
Small-Space: 
An 8 ml sample of 1.0 mg/ml IVIg was placed into the sample cup with the 
nebulizer set up so there was a 1 cm space between the internal reservoir volume and a 
lid from a 50 ml conical tube that fit perfectly above the sample cup.  This geometry 
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allowed for a total headspace volume of about 7   .  The glass plug was placed on top 
of the lid for weight so the jet did not displace the lid.  Vapor particles were thus allowed 
to form within the 7    volume and recollect inside the internal reservoir.  Figure (8B). 
Large-Space: 
An 8 ml sample of 1.0 mg/ml IVIg was placed into the sample cup with the 
nebulizer set up so the reservoir of a 50 ml conical tube attached to the sample cup such 
that the internal reservoir had the entire volume of the sample cup and conical tube to 
circulate during nebulization. This volume of roughly 70   allowed for the greatest 
amount of gas/liquid interface.  Figure (8C). 
 




                  
Figure 8.  Photographic profile of experimental set up during A: No-Space run. B: Small-




An initial concentration of 100 mg/ml IVIg was diluted down to 10.0 mg/ml using 
filtered 0.2 M glycine buffer at pH 4.2 and ultracentrifuged to remove particles >100nm.  
The purified sample was then further diluted to concentrations of 0.5, 1.0, and 5.0 mg/ml 
using filtered 0.2 M glycine buffer at pH 4.2.  An initial sample of each concentration 
was tested on the MFI and NanoSight to get a baseline particle count to compare to 
nebulized samples.  8.0 ml of each concentration was then pipetted into the sample cup of 






was immediately analyzed using the MFI and NTA for particle concentration at the µm 
and nm size range respectively.    
Nebulization Time Dependence 
 
An initial concentration of 100 mg/ml IVIg was diluted into a concentration of 
10.0 mg/ml using filtered 0.2 M glycine buffer at pH 4.2 and ultracentrifuged to remove 
particles > 100 nm.  The sample was then further diluted to 1.0 mg/ml, which was the 
concentration used for all time dependence experiments.  Time points 0, 3, 7, 11, and 15 
min were chosen as representative times for time dependent aggregation which we 
assumed to behave in a classical nucleation and growth manner well represented by an 
exponential form.  8.0 ml of this sample was then loaded into the sample cup and run for 
the length of each time point respectively.  Each sample was run independently, as all 8.0 
ml were required for immediate analysis using the MFI and NTA.    
Volume Dependence 
 
An initial concentration of 100 mg/ml IVIg was diluted to a concentration of 10.0 
mg/ml using filtered 0.2 M glycine buffer at pH 4.2 and ultracentrifuged to remove 
particles > 100 nm.  This sample was then further diluted to 1.0 mg/ml and used for all 
volume dependence experiments.  Volumes of 3.0, 5.0 and 8.0 ml were pipetted into the 
sample cup and nebulized for 15 minutes on high power.  For each volume, the glass plug 
was lowered to just above the liquid to restrict the impinging jet.  In order to obtain 
enough volume to run the MFI and NTA, the 3.0 and 5.0 ml volumes were required to 
run twice and the volumes for the second run were added to the first before samples were 





 Independent variables in this research are nebulizer geometry, solution 
concentration, nebulization time and sample volume.  Total particle concentrations 
analyzed by MFI and NTA depend on these independent variables.  Statistical analysis 
was done by two sample, two tailed, paired t-Tests.  All data were compared to pre-
nebulized controls performed at the beginning of each experiment.  In this case, type I 
errors were controlled by using the Bonferroni correction factor where alpha value (α) of 
0.05 is divided by the number of variables (n) compared to the control (Equation 6).  For 
example, particle concentrations at four solutions concentrations were compared to the  
control, thus correcting the alpha value (    to 0.0125.  
Bonferroni Correction Factor 
  
    
 








CHAPTER THREE: RESULTS 
Viscosity 
 
Viscosity for IVIg concentrations between 1 and 10 mg/ml were tested using a 
model CVO Bohlin Instruments Viscometer.  Measurements were taken 12 times for 
each concentration and averaged.  The distribution of viscosity by concentration is shown 
in Figure (9).  From left to right, bars represent 1.0, 5.0, 8.0, and 10.0 mg/ml 
concentrations of IVIg protein, respectively.   Error bars represent the standard deviation 
of measurements for each concentration. The change in absolute viscosity varies as 
expected with a linear relationship between the log of concentration and log of viscosity,  
as seen in Figure (10) [39].   Using a two tailed, paired t-Test, p-values for 5.0, 8.0 and 





Figure 9.  IVIg absolute viscosity as a function of protein concentration for sample 
concentrations of 1.0 (blue diamond), 5.0 (red square), 8.0 (green triangle) and 10.0 (blue 
cross) mg/ml.  Error bar represents one standard deviation.  Viscosity is significantly 
different than the solution concentration directly preceding it considering Bonferroni 
correction factor (*). 
  
  
Figure 10.  Log of IVIg absolute viscosity as a function of log of protein concentration 
for sample concentrations of 1.0 (blue diamond), 5.0 (red square), 8.0 (green triangle) and 






Density measurements were taken for ultrapure DI water as well as 0.5, 1.0, 5.0, 
and 10.0 mg/ml concentrations of IVIg by measuring the mass of 5.0 ml of each 
concentration using an A&D model GR-202 (A&D®, Ablingdon, UK) analytical 
balance.    
 The results for each concentration can be seen in Table (1).  Dividing the 
experimentally determined value for the density of water by the known value of 0.9982 
g/cm^3 from literature [44], this method calculates the density of pure water to within 
1.0%.  Statistical analysis by two tailed, paired t-Test between each solution 
concentration and water gives p-values of 0.010, 0.02, 0.07 and 0.09 for 0.5, 1.0, 5.0 and 
10.0 mg/ml concentrations respectively.  
Table 1.  Density as a function of concentration for IVIg protein as determined by a mass 





Static surface tension measurements were taken for DI water as well as 0.5, 1.0, 
5.0, and 10.0 mg/ml concentrations of IVIg protein by determining the capillary action at 
each concentration and solving for surface tension using experimentally determined 
density and Ɵ of meniscus at 20°C.  The experimentally determined value for DI water 
(0.9886 g/cm^3) was used and since it was determined there was no significant difference 
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in density between concentrations of IVIg, the average of all values (0.9980 g/cm^3) was 
used for all concentrations to solve for surface tension.  Figure (11) shows the average 
surface tension for each protein concentration over three trials.  Standard deviation was 
determined by calculating the surface tension for each trial.  Statistical comparison 
between water and solution concentrations by two tailed, paired t-Test gave p-values of 
0.04, 0.01, 0.43, and 0.02 for 0.5, 1.0, 5.0 and 10.0 mg/ml respectively.   
 
Figure 11.  Surface tension as a function of IVIg protein concentration as calculated 
through experimental capillary action.  Bars represent DI water (blue), 0.5 (red), 1.0 
(green), 5.0 (purple) and 10.0 (light blue) mg/ml concentrations.  Error bars represent one 
standard deviation.  Surface tension is significantly different than DI water considering 
Bonferroni correction factor (*). 
 




Measurements of triiodide ions (I3
-
) were taken using a USB-ISS-UV/VIS (Ocean 
Optics, Inc., Dunedin, FL) UV-Spectrometer.  A solution of IVIg at 1.0 mg/ml and 







radicals (OH) through cavity collapse, creating local regions of high temperature and 
pressure [33].  The hydroxyl radicals then form hydrogen peroxide (      that can 
oxidize the KI solution.  The resulting formation of potassium hydroxide (KOH) liberates 
iodide ions (  ) which later form iodine (  ) and finally react with another free  
  to form 
I3
-
.   
          
             
                    
     
        
The absorbance spectrum from 300 – 400 nm at time points every three minutes is 
shown in Figure (12).  The bottom line in blue represents the sample before nebulization 
and every line after is the UV absorbance spectrum at time 3, 6, 9, 12, and 15 minutes of 
nebulization exposure.  Measurements were taken over this range in wavelengths to 
display a rise in the peak absorbance at 350 nm.  By far the largest increase in absorbance 
is during the first 3 minutes of nebulization.  This is most likely due to this being the time 
frame where the greatest amounts of iodide ions are available for I3
-
 formation.   
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Figure 12. UV-Spectrum of     absorption as a function of time for samples taken before 
nebulization 0 min (blue), 3 (red), 6 (green), 9 (purple), 12 (light blue) and 15 (orange) 
minutes. 
 
 It is a well-known practice by pharmaceutical scientists to measure ‘turbidity’ of a 
protein solution after storage or upon solution perturbation.  Turbidity, also known as 
opalescence, is the term used to describe the cloudiness or haze in solution [40].  When 
using a UV-Spectrometer, turbidity depends on the sample path length, protein 
concentration, and size of the scatterer (protein/aggregates/particles).  Therefore, an 
increase in turbidity for the same pathlength and concentration can occur due to an 
increase in the size of scatterers, or an increase in concentration of scatterers, or both.  
This makes an increase in turbidity an indication of an increase in protein aggregation in 
protein solutions.   
Figure (13) shows an example of lower concentration KI (2M vs 8.675M from 
Figure (12)).  In this case, there is not enough free iodine ions to form triiodide in great 
amounts and as a result, there is not a significant peak at 350 nm as compaired with all 
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other wavelengths.    In contrast, as aparent in Figure (12), high concentration of KI 
results in a very defined peak at 350 nm. 
Figure 13. UV-Spectrum of I3
- 
absorption as a function of time for samples taken before 
nebulization 0 min (blue) & 15 min (red).   
 
Figure (14) shows concentration of    over time calculated by solving the Beer-
Lambert Law at each time point.  It is observed that the concentration of I3
- 
increases with 
nebulization, suggesting that radicals are being formed by transient cavitation as a result 
of nebulization.  The plot indicates behavior reaching a maximum, while radical 
production should be constantly rising with exposure time. However, the supply of KI to 
form I3
- 
is not infinite and this behavior is an outcome of a limited reactant species. 
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Figure 14.  Triiodide ion (I3
-






An 8.0 ml sample of 1.0 mg/ml IVIg was nebulized on high setting for 15 minutes 
at three different headspace volumes as described in the methods section.  Nebulized 
samples were immediately analyzed using MFI and NTA.  Results from the MFI in 
Figure (15) demonstrate a statistically significant change in the number of aggregated 
particles within 2 and 40 µm. Aggregate counts decrease as the available head space in 
the nebulizer is reduced.   This eliminates the formation of the atomizing jet, and 
eventually eliminating any gas-liquid interface.  Although the results from the NTA in 
Figure (16) exhibit higher measurement uncertainty due to low particle concentrations 
within 1 and 1000 nm, obvious statistical difference in particle concentration between 
runs with a gas-liquid interface and those without is maintained.  Statistical comparison 
of MFI data between the pre-nebulized and nebulized samples by two tailed, paired t-Test 
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gave p-values of 0.03, 0.001, and 9.5E-4 for No-Space, Small-Space and Large-Space 
nebulizer geometries respectively.  Statistical comparison of NTA data between the pre-
nebulized and nebulized samples by two tailed, paired t-Test gave p-values of 0.90, 0.01, 
and 0.007 for No-Space, Small-Space and Large-Space nebulizer geometries 
respectively.  The reader is cautioned in jumping to the conclusion that aggregation is 
eliminated when headspace is eliminated. When data is observed at a finer scale, 
differences are seen even with zero liquid-gas interfaces. Except when specified, all 
results presented for the remainder of this work will be for nebulizer geometries with no 
head space, thus isolating cavitation as the primary means of protein aggregation.   
Figure 15. Concentration of IVIg particles as a function of head space in the nebulizer as 
calculated using MFI.  Bars represent samples analyzed before nebulization pre-Neb 
(blue), and after 15 minutes of nebulization for nebulizer set up with No-Space (red), 
Small-Space (green) and Big-Space (purple).  Error bars represent one standard 
deviation.  Particle concentration is significantly different from pre nebulized control 







Figure 16.  Concentration of IVIg particles as a function of head space in the nebulizer as 
calculated using NTA.  Bars represent total concentration of samples analyzed before 
nebulization pre-Neb (blue), and after 15 minutes of nebulization for nebulizer set up 
with No-Space (red), Small-Space (green) and Big-Space (purple).  Error bars represent 
one standard deviation.  Particle concentration is significantly different from pre-
nebulized control considering Bonferroni correction factor (*). 
Time Dependence 
 
An 8.0 ml sample of 1.0 mg/ml IVIg was nebulized for time points 3, 7, 11, and 
15 minutes.  Each time point represents its own individual run, as all 8.0 ml was required 
for analysis using MFI and NTA.  Particle concentrations within 2 and 40 µm increase as 
nebulization time increases for samples of the same protein concentration when analyzed 
with MFI, as seen in Figure (17). The concentration of aggregates rises from 
approximately 1000 to 7000 particles per ml, representing a 7-fold increase. However, it 
is difficult to draw any conclusions from the NanoSight (1 to 1000nm particle size range) 
because particle concentrations are below the minimum levels recommended by the 




Figure (18).  NanoSight tracking analysis (NTA) requires particle concentrations of 
        particles/ml in order to be accurate.  Statistical comparison of MFI data 
between the pre-nebulized and nebulized samples by two tailed, paired t-Test gave p-
values of 0.005, 0.001, 0.001and 0.001 for 3, 7, 11, and 15 minute time points 
respectively.  Statistical comparison of NTA data between the pre-nebulized and 
nebulized samples by two tailed, paired t-Test gave p-values of 0.05, 0.001, 0.002 and 
0.001 for 3, 7, 11, and 15 minute time points respectively. 
It is also important to note that each figure representing a different experimental 
set-up also represents a completely different sample prep.  In other words, every figure 
represents a different ‘lot’ of IVIg that was separately ultracentrifuged, diluted to 
concentration and stored.  Therefore, trends in data, rather than absolute particle 
concentrations, should be considered when comparing figures to each other.   
Figure 17.  Particle concentration as a function of nebulization time using MFI.  Bars 
represent total particle concentration of samples analyzed before nebulization pre-neb 







respectively.  Particle concentration is significantly different from pre-nebulized control 
considering Bonferroni correction factor (*). 
 
 
Figure 18.  Particle concentration as a function of nebulization time using NTA.  Bars 
represent total particle concentration of samples analyzed before nebulization pre-neb 
(blue) and nebulized for 3 (red), 7 (green), 11(purple) and 15 (light blue) minutes 
respectively.  Error bars represent one standard deviation.  Particle concentration is 
significantly different from pre-nebulized control considering Bonferroni correction 
factor (*). 
 
Figure (19) shows results from experiments where filtered buffer was nebulized 
for 15 minutes, followed by IVIg addition to a solution concentration of 1.0 mg/ml.  This 
solution was then allowed to sit in order to compare the rate of aggregation over time for 
protein that is not exposed to cavitation.  These data are compared to particle 
concentrations as a result protein that is nebulized for 15 minutes.  This graph indicates 
that no significant increase in aggregate formation is taking place over a four hour period 
due to nucleation alone, indicating that increased particle counts after 15 minutes of 






Figure 19.  Particle concentration as a function of time using MFI.  Lines represent 1.0 
mg/ml IVIg nebulized for time points between 3 & 15 minutes(blue), and IVIg added to 
buffer that has been nebulized for 15 minutes (red).  
Volume Dependence 
 
1.0 mg/ml IVIg was nebulized in 3.0, 5.0 and 8.0 ml volumes.  All samples were 
nebulized for 15 minutes.  Based on traditional cavitation theory, more cavitation events 
are expected as the energy per unit mass is increased. Energy per unit mass can be 
explored using a constant protein concentration solution with variable sample volumes. In 
the 2 – 40 µm particle size range as measured by MFI, particle concentrations generated 
as a result of 15 minutes of continuous nebulization increase as the sample volume was 
decreased from 8.0 to 5.0 ml, Figure (20).  When the sample volume was decreased to 5.0 
ml from 8.0 ml, representing a 37.5% change in the energy per unit volume or mass, the 
particle concentration increased by 30%. This was not the case when the volume was 
dropped from 5.0 ml to 3.0 ml (representing 40% in volume), where a 49% decrease is 
observed.  Particle concentrations at the nm scale as analyzed by NTA exhibited ‘clean’ 
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or no increase in particle concentration for all conditions with no statistically significant 
trend in the data; Figure (21).  Statistical comparison of MFI data between the pre-
nebulized and nebulized samples by two tailed, paired t-Test gave p-values of 0.01, 
0.004, and 0.009 for 3.0, 5.0, and 8.0 ml volumes respectively.  Statistical comparison of 
NTA data between the pre-nebulized and nebulized samples by two tailed, paired t-Test 
gave p-values of 0.73, 0.12, and 0.26 for 3.0, 5.0, and 8.0 ml volumes respectively. 
Figure 20.  Particle concentration as a function of sample volume using MFI.  Bars 
represent total particle concentration for samples analyzed before nebulization pre-neb 
(blue), and nebulized for 15 minutes at a volumes of 3.0 (red), 5.0 (green), and 8.0 
(purple) ml respectively.  Error bars represent one standard deviation.  Particle 
concentration is significantly different from pre-nebulized control considering Bonferroni 








Figure 21.  Particle concentration as a function of sample volume using MFI.  Bars 
represent total particle concentration for samples analyzed before nebulization pre-neb 
(blue), and nebulized for 15 minutes at a volumes of 3.0 (red), 5.0 (green), and 8.0 




Concentration of IVIg was increased from 0.5 to 10.0 mg/ml and nebulized for 15 
minutes.  Figure (22) shows results of particle concentrations in the 2 – 40 µm size range 
as measured by MFI during 15 minute continuous nebulization runs as a function of 
concentration.  The concentration of particles increases approximately monotonically 
with increasing concentration from 0.5 to 5.0 mg/ml.  As protein solution concentration 
continues to rise above 5.0 mg/ml, the concentration of aggregated protein particles 
observed appears to decreases although not statistically significant.  Particle generation as 
analyzed by NTA had large error within the sample due to low particle concentration.  
Statistical comparison of MFI data between the pre-nebulized and nebulized samples by 
two tailed, paired t-Test gave p-values of 0.14, 0.013, 0.008 and 0.007 for 0.5, 1.0, 5.0 
and 10.0 mg/ml concentrations respectively.  Statistical comparison of NTA data between 
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the pre-nebulized and nebulized samples by two tailed, paired t-Test gave p-values of 
0.37, 0.04, 0.23 and 0.81 for 0.5, 1.0, 5.0, and 10.0 mg/ml concentrations respectively. 
 
Figure 22.  Particle concentration as a function of sample concentration using MFI.  Bars 
represent total particle concentration for samples analyzed before nebulization pre-Neb 
(blue), as well as nebulized for 15 minutes at concentrations 0.5 (red), 1.0 (green), 5.0 
(purple) and 10.0 (light blue) mg/ml respectively.  Error bars represent one standard 
deviation.  Particle concentration is significantly different from pre-nebulized control 









Figure 23.  Particle concentration as a function of sample concentration using NTA.  
Bars represent total particle concentration for samples analyzed before nebulization 
buffer (orange) and pre-Neb (blue), as well as nebulized for 15 minutes at concentrations 
0.5 (red), 1.0 (green), 5.0 (purple) and 10.0 (light blue) mg/ml respectively.  Error bars 
represent one standard deviation.   
 
The results are not the same when a gas-liquid interface is introduced into the 
systems; Figure (24) and Figure (25).  Small-Space nebulizer geometry was set up as 
described in the methods section and concentrations of 0.5, 1.0, 5.0 and 10.0 mg/ml IVIg 
protein was prepared and nebulized for 15 minutes.  Unlike the no headspace results, the 
concentration of aggregated protein measured after processing rises inversely to protein 
solution concentration in the 2 to 40 m range as measured by MFI.  Moreover the final 
concentrations represent another order of magnitude increase over the previous results.  
The concentration of submicron protein aggregates also falls as the solution protein 
concentration increases. The change is nearly two orders of magnitude, and is at a level in 
100s of million per ml; a massive difference from any measurement so far.  Statistical 
comparison of MFI data between the pre-nebulized and nebulized samples by two tailed, 
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paired t-Test gave p-values of 1.8E-4, 04.9E-4, 0.032 and 0.29 for 0.5, 1.0, 5.0 and 10.0 
mg/ml concentrations respectively.  Statistical comparison of NTA data between the pre-
nebulized and nebulized samples by two tailed, paired t-Test gave p-values of 0.003, 
2.3E-4, 0.03 and 0.54 for 0.5, 1.0, 5.0, and 10.0 mg/ml concentrations respectively. 
Figure 24.  Particle concentration after 15 minutes of nebulization as a function of IVIg 
solution concentration with a small head space.  Bars represent pre-nebulized samples of 
buffer (orange), 1.0 mg/ml IVIg (blue), as well as 10.0 (red), 5.0 (green), 1.0 (purple) and 
0.5 (light blue) mg/ml IVIg protein concentration respectively.  Error bars represent one 
standard deviation. Particle concentration is significantly different from pre-nebulized 










Figure 25.  Particle Concentration after 15 minutes of nebulization as a function of IVIg 
solution concentration with a small head space as analysed using NTA.  Bars represent 
IVIg protein concentrations before nebulization pre-Neb (light blue) as well as at 0.5 
(blue), 1.0 (red), 5.0 (green) and 10.0 (purple) mg/ml concentrations respectively.  Error 
bars represent one standard deviation. Particle concentration is significantly different 













CHAPTER FOUR: DISCUSSION 
Gas - Liquid Interface 
 
Proteins are amphiphilic, meaning a single molecule contains both hydrophobic 
and hydrophilic regions.  At liquid–gas interfaces, the proteins will rearrange to expose 
the hydrophobic regions to the gas phase and hydrophilic regions to the aqueous phase.  It 
is well documented that unstable therapeutic proteins may require only minor energy 
input to irreversibly alter protein conformations resulting in aggregation [1-5].  
Experiments were conducted to verify how to effectively and completely eliminate the 
contribution of a gas-liquid interface degradation pathway, so the current study was 
isolating aggregation via cavitation (stable or transient).  Figures (15) and (16) 
demonstrate the number of aggregated particles decrease by approximately an order of 
magnitude at the micron as well as sub-micron range as the available head space in the 
nebulizer is reduced. This eliminates the formation of the atomizing jet and eventually 
eliminates any gas–liquid interface.  The concentration of aggregates increases 
significantly when a gas liquid interface is allowed.   
The presence of a gas-liquid interface not only changes the total concentration of 
protein aggregation, but also changes the influence of solution properties on aggregate 
formation, especially at the higher concentrations and in the submicron range. A more 
complete discussion of these results is presented below. 
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It is interesting to note that the regular operations of nebulizers involve a great 
amount of gas–liquid interface by virtue of atomization itself.  Even in cases where the 
gas–liquid interface was allowed during this experiment, the available headspace was 
nowhere near what is involved in drug delivery.  Figure (26) shows a side by side 
comparison of an optional set up for drug delivery (A) and the experimental set up where 
a gas-liquid interface is allowed (B). Considering the great amount of particle generation, 
and therefore protein aggregation measured in this experiment, even a cautious 
investigator would conclude that higher concentrations of protein aggregation would 
occur after normal nebulization delivery. We acknowledge that the lung is full of 
macrophage which could likely clean the majority of these problem particles prior to 
absorption into the blood stream, but these results suggest that a immunogenicity study 
on lung cells should be conducted to understand the threats of nebulized proteins.  
 
          
Figure 26.  A: Nebulizer set-up with nozzle for drug delivery.  Gas interface exists above 




during small-space headspace dependance experiment.  Gas interface is impinged by cap 




Energy per Mass 
 
The rate and intensity of cavitation is a function of the amount of energy put into 
the acoustic wave, frequency of excitation, vapor pressure of the fluid, and fluid density.  
In addition to altering the surface tension and viscosity, methods for reducing the number 
of variables influencing the outcomes needed to be addressed. One could envision a 
method of equalizing the energy per mass placed into each sample regardless of solution 
density simply by making small adjustments of the sample volume.  However, in 
nebulizers, the acoustic waves are focused into the center of the sample reservoir using a 
liquid horn. Additionally, the complexity of wave intensity is a function of reflection off 
all surfaces, especially the gas-liquid interface.  This complicates the ability to understand 
how altering sample volume will impact the average energy per unit mass in the sample 
volume. Particle generation as a function of sample volume for a single solution density 
was measured to identify a range where the expected decrease in sample volume resulted 
in a proportional increase in particle formation.  The normal operating sample volume of 
8.0 ml could be safely decreased to 5.0 ml, causing increased particle generation rate or 
increasing cavitation as can be seen in Figure (20).  When the sample volume reduced 
below 5.0 ml, the ability to predict the effect of decreasing volume as increasing energy 
density is compromised. 
 Possible reasons for this could be due to a decreased volume beyond the 
MABISMist™ II Ultrasonic Nebulizer’s suggested operating volume.  Since the acoustic 
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waves are focused in the center of the sample volume, a parameter that cannot be 
adjusted, altering the sample volume beyond 5.0 ml could lead to unexpected variability 
with respect to the acoustic energy field’s focus and reflection off surfaces.  Thus, 
concentration of aggregates for volumes below 5.0 ml may not be a result of the full 
energy input into the system.    
Increased Aggregation over Time 
 
Concentration of triiodide as a result of nebulization over time was determined by 
solving the Beer-Lambert Law for UV-Spec absorbance of IVIg protein in the presence 
of KI as seen in Figure (14).  The concentration increases with time as more cavitation 
events occur, releasing more radicals into solution to carry out the necessary triiodide 
reaction.  An exception to this was recorded between 12 and 15 minutes of nebulization 
where the curve seems to plateau or only increase slightly as compared to other time 
periods.  One potential reason for this plateau in concentration is because the available 
iodide in solution is likely exhausted.  The comparably large increase between 0 and 3 
minutes of nebulization adds to the validity of this theory since the greatest abundance of 
free iodide exists during this time.   
Figure (17) plots the concentration of particles measured using the MFI as a 
function of nebulization time.  This plot also shows an increase in particle concentration 
generated over time.  By plotting the results of Figure (17) alongside the results of Figure 
(14), it can be seen that the increase in I3
- 
concentration exhibits the same trend as the 
particle concentration with the exception that particle concentration continues to increase 
in time even after I3
-
 concentration plateaus, Figure (27).  
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Figure 27. Triiodide ion concentration (blue) and total particle concentration (red) as a 
function of nebulization time.  
 
This relationship is interesting because the correlation in behavior suggests that 
IVIg aggregation during nebulization is infact a product of energy delivered via 
cavitation within the sample reseravoir.  The divergence of the two plots after 12 minutes 
as I3
- 
concentration plateaus and particle concentration continues to increase is also 
expected since particles will continue to aggregate in the prescence of exhisting 
aggregates while I3
-
 can only form as long as there are free iodide available for triiodine 
formation. 
Coupling the correlation between triiodide formation and aggregate concentration 
as a function of time with the observation that triiodide concentration does not rise in 
nebulized buffer solutions and that IVIg appears to scavange radicals necessary to form 
triiodides from KI, there is strong support for the hypothesis that IVIg acts as a nucleation 
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site for cavitation under accoustic forcing similar to plasmid DNA. If this is the case, as 
the concentration rises the number of cavitation sites will rise and higher aggregate 
production rates will be expected.   
This hypothesis is further validated by the observation that higher particle 
concentrations are reported for experiments with a higher baseline particle concentration 
in the pre nebulized control.  Figure (17) begins with a pre nebulized particle 
concentration of about 1000 particles/ml, and reports a maximum particle concentration 
around 6400 particles/ml.  Similarly, Figures (20 & 22) begin with a pre nebulized 
particle concentration around 500 particles/ml, and achieve a maximum particle 
concentrations of 3800 and 3600 particles/ml respectively.  These data can be explained 
by varibility in protein sample preperation and storage.  ‘Dirty’ samples yeilding higher 
particle concentrations after nebulization is consistant with hypothesis that proteins can 
act as a nucleation sight for cavitation.   
Influence of Concentration 
 
As protein bulk solution concentration is increased from 1.0 to 5.0 mg/ml, there is 
a clear increase in protein aggregate concentration after 15 minutes of nebulization. This 
is consistent with the hypothesis that IVIg is acting as a nucleation site for cavitation and 
aggregating as a result of the process of cavitation. It is important to recognize that under 
these conditions viscosity changes from 3.3 to 4.5 mPa*s, thus could also contribute to 
the observed trend. There is no significant difference in experimental values for density 
and surface tension, while protein concentration is altered by one order of magnitude. It is 
likely that the change in solution properties (viscosity, surface tension and density) are 
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less than or equal to the measurement error, leaving only solution concentration as the 
parameter dominating the observed aggregation behavior.  
The exception is the change in trend observed at concentrations higher than 5 
mg/ml.  Increasing solution protein concentration from 5.0 to 10.0 mg/ml, a one-fold 
increase, results in a statistically insignificant decrease in aggregate concentration. The 
change in the solution properties is much different in this range. Surface tension and 
density are unchanged within experimental uncertainty, while viscosity is almost three 
times larger. In this case viscosity has damped out the expect rise in aggregate 
production.   
Probabilistic analysis of computational models of hydrodynamic cavitation 
resulting from a constant driving energy (simulation conducted by Donn Sederstrom for a 
related project) show that the probability of cavitation decreases, as measured by the 
magnitude of the lowest pressure region, as viscosity values increase. In fact, during 
investigations of our exact density and viscosity ranges for the same driving energy, this 
work demonstrated no cavitation is expected for solution concentration above 25 mg/ml. 
Physically, for a given system input energy, the frictional losses due to viscous effects 
consume flow energy that would have otherwise translated into lower pressure regions. In 
other words, the energy of the acoustic wave is more rapidly diffused over the bulk 
volume and consumed by frictional or viscous heating, rather than maintaining large 
pressure fluctuations that generate low pressure regions suitable for cavitation. It is 
important to note that in these studies, the concentration of particles between 1 & 1000 
nm as measured by NTA was unchanged from the control solutions, suggesting that the 
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nucleation size is above 1000nm. From nucleation and growth theory, one would only 
anticipate the absence of small particles if the growth rate was high due to an abundance 
of material in close proximity. The almost singularity nature of a cavitation event is 
consistent with the above description. 
When a gas interface is allowed, measured particle counts increased by 10 fold 
when analysed at the 2 – 40 µm size using MFI as compared with data from Figure (21). 
In contrast to aggregation by cavitation alone, micron and submicron aggregates are 
inversely related to solution protein concentration. The first important observation is that 
submicron aggregation is occurring, unlike under cavitation dominate conditions. The 
smaller nucleation size could be a result of a more super saturate process, or because the 
process is spread out over a larger area and particle growth is limited by diffusion time 
over a long distance to the nucleation site. The second observation is that the number of 
submicron particles decreases as a function of solution concentration. Mass diffusivity, 
by the Stokes-Einstein relationship, is inversely proportional to viscosity [45]. Thus as 
viscosity increases, the diffusion time over the same distance becomes larger. If the 
concentration remained the same, a rise in viscosity would lead to more submicron 
particles as a result of diffusion. However, viscosity is only changing by 38% from 1.0 to 
5mg/ml whereas concentration is rising by 500%. In a system dominated by 
concentration or number of available particles, the growth rate of particles would be 
expected with increases in the lowest size particle measured.  This assumes that the 
number of protein molecules at the interface is continually rising and does not saturate. 
This would be true if (1) IVIg was a surface active agent and surface tension continued to 
 
55 
fall with concentration or (2) IVIg was not a surface active agent and the surface tension 
remained constant as a function of concentration. The latter is observed experimentally. 
Thus the observed trend would be consistent for an interface driven phenomena. The 
third observation is that when a gas interface exists, the elimination of cavitation at high 
viscosity does not drown out the interface driven aggregation process.  
Mitigation strategies 
Based off the data collected in this study, aggregation by cavitation can be 
mitigated by extremely high concentrations or raising solution viscosities. Extrapolation 
of the concentration data suggests that solutions above 25 mg/ml would result in 
aggregate concentrations statistically similar to unprocessed solutions. 
Aggregation, primarily driven by a gas-liquid interface, would also be mitigated 
by very high solution concentrations. However, if the immunogenicity of a protein 
therapeutic is dominated by the submicron particles, then solution concentrations above 
5.0 mg/ml would be suitable. Alternate techniques involving formulations containing 








CHAPTER FIVE: CONCLUSION 
The objective of this work was to assess the impact of ultrasonic nebulization on 
IVIg aggregation.  It was determined that the gas-liquid interface can be a strong driving 
mechanism in IVIg aggregation at the micron and submicron range.  IVIg was also 
identified as a nucleation site for transient cavitation.  Transient cavitation aggregates 
IVIg molecules in the micrometer size range, not at the submicron range.  Finally, 
transient cavitation can be mitigated by utilizing larger IVIg concentrations.  Based on 
the results from this research, we hypothesize concentrations above 25 mg/ml would 
eliminate particle formation as a result of transient cavitation.  These viscosities would 
also increase the time it takes for IVIg to diffuse to the gas-liquid interface and mitigate 
aggregation via that mechanism.   
 Future studies should focus on creating a larger data set with respect to variables 
such as fluid properties, concentration, volume, portentous compound, and source of 
cavitation.  First, density and surface tension should be reevaluated to obtain statistically 
significant values between protein concentrations.  This would help to refine and 
reevaluate theories on cavitation induced protein aggregation.  Second, a larger range of 
concentrations should be tested to evaluate if trends in protein aggregate formation from 
the current research are continued.  These concentrations should be representative of 
those that would be typical for process, shipping, and delivery.  Third, volume 
dependence should be reanalyzed in an attempt to better understand to what extent the 
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energy per mass relationship plays in cavitation induced protein aggregation.  In this 
case, it might be necessary to find a cavitation source with fewer variables to control than 
ultrasonic nebulization.  Next, many other proteins should be studied for possible 
immunogenic effects due to cavitation.  Protein aggregation due to cavitation using IVIg 
would suggest this process could take place with other therapeutic proteins.  Due to 
known immunogenic responses to submicron protein aggregation, it would be worthwhile 
to conduct cavitation mitigation studies on all protein therapeutics before patient 
administration.  Finally, other sources of cavitation should be investigated in order to 
better mitigate cavitation during bioprocessing.  All sources of cavitation should be 
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